BlueRock Therapeutics LP

In News

FDA grants Orphan Drug designation to BlueRock's RP cell therapy - Glance by Eyes On Eyecare

Glance by Eyes On Eyecare - Jan 23, 2026

RoslinCT and BlueRock Therapeutics Partner to Expand Access to Clinical-Grade Pluripotent Cell Lines for Cell Therapy Developers - Business Wire

Business Wire - Jul 08, 2026

FDA grants Orphan Drug Designation to BlueRock Therapeutics’ investigational cell therapy OpCT-001 - bayer.com

bayer.com - Jan 22, 2026

BlueRock Therapeutics reports positive 36-month results from Phase I trial of bemdaneprocel for treating Parkinson’s disease - bayer.com

bayer.com - Oct 07, 2025

Bayer to acquire Perfuse Therapeutics, expanding ophthalmic pipeline - Glance by Eyes On Eyecare

Glance by Eyes On Eyecare - May 07, 2026

Bayer claims cell and gene therapy first in Parkinson’s research - europeanpharmaceuticalreview.com

europeanpharmaceuticalreview.com - Sep 23, 2025

BlueRock Therapeutics to incorporate wearable and invisible contactless digital health technologies from Rune Labs and Emerald Innovations in Parkinson's disease clinical trial - PR Newswire

PR Newswire - Mar 14, 2023

BlueRock Therapeutics Assessing the Potential of Cell Therapy for Parkinson Disease With Phase 1 Trial for Bemdaneprocel - CGTLive®

CGTLive® - Jul 22, 2024

BlueRock Therapeutics investigative cell therapy bemdaneprocel for treating Parkinson’s disease receives Pioneering Regenerative Medical Product designation in Japan - bayer.com

bayer.com - Dec 17, 2025

Bayer opens new facility on its West Berkeley campus to launch cell therapy treatments - Berkeleyside

Berkeleyside - Dec 07, 2023

BlueRock Receive FDA clearance of IND for Investigational iPSC-derived Cell Therapy OpCT-001 - BioInformant

BioInformant - Sep 09, 2024

First Parkinson’s disease patient treated in BlueRock’s pivotal Phase III trial of investigational cell therapy bemdaneprocel - bayer.com

bayer.com - Sep 22, 2025

Stay Informed

Join our mailing list for the latest report releases and upcoming event notifications.

Headquartered in Boston, Mass., for over 50 years, BCC Research takes pride in being your trusted custom research and data analysts. Our mission is to provide businesses with reputable data and market research reports, so that they gain new perspectives into their field and better understand their target audience. We enable companies to access reliable information, accurate forecasts, and actionable insights, so that they may become leaders in their industry.

AI Sentiment